Bibliographic record
Abstract
Canada’s Drug Agency (CDA-AMC) recommends that Blincyto be reimbursed by public drug plans for the treatment of patients with Philadelphia chromosome (Ph)–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy if certain conditions are met. Blincyto should only be covered to treat adult and pediatric patients whose Ph-negative, CD19-positive B-cell ALL is in remission, regardless of whether patients still have detectable traces of cancer (minimal residual disease [MRD]). Remission is a response to treatment in which signs of cancer have disappeared, but it does not always mean the cancer is cured. Remission encompasses complete remission (CR) or CR with incomplete peripheral blood count recovery (CRi), which means the disease is in CR, but blood cell levels have not yet fully returned to normal. Blincyto should be initiated in the front-line consolidation phase of multiphase chemotherapy (treatment phase to improve remission). Blincyto should only be reimbursed if it is prescribed by clinicians with expertise in managing ALL in specialized cancer centres and if the cost of Blincyto is reduced.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.021 | 0.007 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".